Deal Watch: Dianthus Will Reach Public Markets Via Reverse Merger With Stalled-Out Magenta

After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.

Deal Watch 2021
• Source: Shutterstock

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

With development of its conditioning agent for leukemia patients undergoing stem cell transplants stalled due to significant dose-limiting toxicities seen in three clinical trial patients, Magenta Therapeutics, Inc. concluded its evaluation of strategic alternatives on 3 May by agreeing to a reverse merger with Dianthus Therapeutics

More from Deal Watch

More from Deals